BioSpace News Archive

Allergan Aesthetics, an AbbVie company, (NYSE: ABBV) announced today that eight scientific abstracts from its leading portfolio of aesthetic products and treatments will be presented at the American Society for Dermatologic Surgery (ASDS) meeting taking place October 6-10 in Denver.

Today, the U.S. Food and Drug Administration approved Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age.

PDS Biotechnology Corporation announced that PDS Biotech granted nonstatutory stock options to Rory Cullinane, PDS Biotech’s Vice President, Quality Assurance, to purchase 70,000 shares of PDS Biotech common stock as a material inducement to his employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635 and PDS Biotech’s 2019 Inducement Plan, as amended.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 8 new employees with a grant date of October 3, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Curis, Inc. announced that on October 3, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 121,650 shares of Curis common stock to two new employees, with a grant date of October 3, 2022.

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced that it has called an extraordinary general meeting of shareholders, to be held at 9:30 a.m. on November 15, 2022.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a non-executive employee to purchase an aggregate of 10,000 shares of common stock.

LimaCorporate proudly announces the FDA approval of a new shoulder platform focused on versatility and Operating Room efficiency.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Company’s common stock has been selling for a low price per share for a substantial period of time.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 22,500 shares of its common stock and the grant of 15,000 restricted stock units to one new employee.